Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15856MR)

This product GTTS-WQ15856MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15856MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12507MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ6407MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ5255MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ3252MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ5468MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ2932MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ6109MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ11672MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW